Last reviewed · How we verify
Intratumoral injection of ipilimumab and AS01b
Intratumoral injection of ipilimumab and AS01b is a Small molecule drug developed by Universitair Ziekenhuis Brussel. It is currently in Phase 1 development.
At a glance
| Generic name | Intratumoral injection of ipilimumab and AS01b |
|---|---|
| Sponsor | Universitair Ziekenhuis Brussel |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Intratumoral Injection of Autologous CD1c (BDCA-1)+ MyDC, Avelumab, and Ipilimumab Plus Systemic Nivolumab (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Intratumoral injection of ipilimumab and AS01b CI brief — competitive landscape report
- Intratumoral injection of ipilimumab and AS01b updates RSS · CI watch RSS
- Universitair Ziekenhuis Brussel portfolio CI
Frequently asked questions about Intratumoral injection of ipilimumab and AS01b
What is Intratumoral injection of ipilimumab and AS01b?
Intratumoral injection of ipilimumab and AS01b is a Small molecule drug developed by Universitair Ziekenhuis Brussel.
Who makes Intratumoral injection of ipilimumab and AS01b?
Intratumoral injection of ipilimumab and AS01b is developed by Universitair Ziekenhuis Brussel (see full Universitair Ziekenhuis Brussel pipeline at /company/universitair-ziekenhuis-brussel).
What development phase is Intratumoral injection of ipilimumab and AS01b in?
Intratumoral injection of ipilimumab and AS01b is in Phase 1.